Skip to main content

RGEN Repligen Corporation

Healthcare

172.95 -3.99 -2.26% Close 11/2
Since 2024-12-02 +17.6%
Open
178.12
High
178.12
Low
172.51
Prev close
176.94
Volume
1.6M
Amplitude
3.17%
P/B
5.4
Revenue YoY (TTM)
+13.8%
52W 100.99 198.87

Is Repligen Corporation a buy? Fundamentals and valuation first

As of 2026-10-30

Momentum: Good, Risk / liquidity: Good; Valuation: Pricey, Growth: Weak.

Valuation Pricey Free-cash-flow yield is Good, but Price / book is Expensive.
TTM P/E -842.57 N/A
Price / book 5.41 84th percentile Expensive
Free-cash-flow yield (%) 0.94 51th percentile Good
US Stock Backtest in Python: Price-to-Book Ratio StrategyQuality Factor Investing: A US Quality Value Backtest
Quality Neutral FCF margin, TTM is Good, but ROE, TTM is Average.
ROE, TTM (%) -0.56 39th percentile Average
Operating margin, TTM (%) 2.35 41th percentile Average
FCF margin, TTM (%) 13.18 67th percentile Good
Quality Factor Investing: A US Quality Value Backtest
Growth Weak Revenue growth, TTM YoY is Good, but Diluted EPS growth, TTM YoY is Lagging.
Revenue growth, TTM YoY (%) 13.8 67th percentile Good
Diluted EPS growth, TTM YoY (%) -1,150 3th percentile Lagging
Momentum Good 60-day return is Top; 240-day return is Good.
60-day return (%) 10.98 86th percentile Top
240-day return (%) 16.13 68th percentile Good
Momentum Trading Strategy: A 12-1 Momentum Backtest
Risk / liquidity Good 20-day dollar volume is Top, but 60-day annualized volatility is Average.
20-day dollar volume 257,713,460 94th percentile Top
60-day annualized volatility (%) 46.98 53th percentile Average
Factor Investing Explained: 10 Classic Factors in US Stocks

Repligen Corporation (RGEN) today

2 quant signals active · As of 2026-10-30

Win rate and excess are historical post-trigger stats vs the market. Click a signal for its full definition and samples; history does not predict future results.

FinLab Studio

From Repligen Corporation to every stock like it

AI finds several complementary traits of Repligen Corporation across different dimensions, combines them into a multifactor strategy, and backtests it against the market.

Screen stocks like Repligen Corporation

Repligen Corporation (RGEN) peers and tracking

Watchlist

This page refreshes daily after the close. Add Repligen Corporation to your watchlist to track signal changes on your next visit.

Repligen Corporation (RGEN) quant signal backtests

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 91.43%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

Momentum Trading Strategy: A 12-1 Momentum Backtest
22 historical occurrences (since 2016-08-03)

Average forward return after Top-quintile 6-month momentum

20-day: Win 68.2%, Sample 22, Median +2.23%, Excess +1.86%, Beat mkt rate 59.1%

60-day: Win 57.1%, Sample 21, Median +3.07%, Excess -0.96%, Beat mkt rate 42.9%

120-day: Win 33.3%, Sample 21, Median -4.7%, Excess -8.35%, Beat mkt rate 28.6%

120 days after: historical avg -0.61%

20-day +3.52%
60-day +3.02%
120-day -0.61%
20-day
60-day
120-day
Win
68.2%
57.1%
33.3%
Sample
22
21
21
Median
+2.23%
+3.07%
-4.7%
Excess
+1.86%
-0.96%
-8.35%
Beat mkt rate
59.1%
42.9%
28.6%

Over 21 occurrences, 120-day forward avg declined 0.61%, lagged the market by 8.35 pts; win rate 33.3%.

EPS surprise beat

Active · now 14.52%

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

PEAD: Post-Earnings Announcement Drift Backtest
37 historical occurrences (since 2015-05-07)

Average forward return after EPS surprise beat

20-day: Win 50%, Sample 34, Median -0.12%, Excess +0.59%, Beat mkt rate 55.9%

60-day: Win 55.9%, Sample 34, Median +5.97%, Excess +1.23%, Beat mkt rate 47.1%

120-day: Win 66.7%, Sample 33, Median +8.4%, Excess +4.61%, Beat mkt rate 48.5%

120 days after: historical avg +11.11%

20-day +1.01%
60-day +3.85%
120-day +11.11%
20-day
60-day
120-day
Win
50%
55.9%
66.7%
Sample
34
34
33
Median
-0.12%
+5.97%
+8.4%
Excess
+0.59%
+1.23%
+4.61%
Beat mkt rate
55.9%
47.1%
48.5%

Over 33 occurrences, 120-day forward avg gained 11.11%, beat the market by 4.61 pts; win rate 66.7%.

More history: Market-wide momentum baseline, Signals not active now

Market-wide momentum baseline

Across 99,493 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.42%, a 58.4% positive-return rate, and +3.08 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

16 times historically; 60-day forward avg +5.08%, win rate 64.3%, beating the market by +2.16 pts on average.

Filed revenue acceleration

Pending

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

14 times historically; 60-day forward avg +8.4%, win rate 64.3%, beating the market by +6.38 pts on average.

Method and limits

  • Returns use us_price:adj_close, adjusted for splits and dividends where available.
  • Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
  • Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
  • The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
  • Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
  • Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.